JOINN(603127)2025-01-24 10:25Revenue Projections - The company expects to achieve operating revenue of approximately RMB 1,917.42 million to RMB 2,119.25 million in 2024, representing a decrease of about RMB 257.24 million to RMB 459.07 million, or a year-on-year decline of approximately 10.8% to 19.3%[1]. Profit Projections - The net profit attributable to shareholders is projected to be around RMB 58.69 million to RMB 88.03 million, a decrease of approximately RMB 308.96 million to RMB 338.30 million, reflecting a year-on-year decline of about 77.8% to 85.2%[1]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is expected to be approximately RMB 17.89 million to RMB 26.84 million, down by about RMB 310.73 million to RMB 319.67 million, indicating a year-on-year decline of approximately 92.0% to 94.7%[2]. - The net profit from laboratory services is estimated to be around RMB 43.30 million to RMB 54.92 million, a decrease of approximately RMB 418.37 million to RMB 429.99 million, reflecting a year-on-year decline of about 88.4% to 90.9%[2]. Previous Year Performance - The company reported a previous year's operating revenue of RMB 2,376.49 million and a net profit of RMB 396.99 million attributable to shareholders[6]. - The previous year's net profit after deducting non-recurring gains and losses was RMB 337.56 million, with laboratory services contributing RMB 473.29 million[6]. Factors Affecting Performance - The decline in performance is attributed to intensified industry competition, increased order pressure, and reduced profit margins[7]. - The market price decline of biological assets negatively impacted the company's performance due to fair value changes[8]. Forecast Accuracy - The company does not foresee any significant uncertainties affecting the accuracy of this performance forecast[9]. - The data provided is preliminary and subject to change, with the final figures to be disclosed in the official 2024 annual report[10].